Sponsor hub

Icahn School of Medicine at Mount Sinai clinical trial failures

Review 51 stopped clinical trials from Icahn School of Medicine at Mount Sinai, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 7 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials51
Likely biological signals7
Shown below51

Dominant stop reasons

OPERATIONAL
25
OTHER/UNKNOWN
18
EFFICACY/FUTILITY
6
REGULATORY
1
SAFETY
1

Notable sponsors

Icahn School of Medicine at Mount Sinai
51

Related phases

Phase II
24
Phase IV
14
Phase III
5
Unknown
5
Phase I
3

Crawlable stopped-trial records

Open Explore

Showing up to 51 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT02225600: The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults

Unknown Borderline Personality Disorder trial by Icahn School of Medicine at Mount Sinai. Stop reason: OPERATIONAL.

Study was halted during COVID pandemic. However, PI is currently reconnecting with a compounding pharmacy to re-establish supply of the oxytocin and updating cost estimates. We are hoping to resume the pilot work with oxytocin once it is clarified.

NCT06092216: Spesolimab in Pyoderma Gangrenosum

Phase II Pyoderma Gangrenosum trial by Icahn School of Medicine at Mount Sinai. Stop reason: OPERATIONAL.

The funding sponsor terminated our study and will conduct a multicenter national study in its place.

NCT05879458: Ritlecitinib in CTCL

Phase II CTCL trial by Icahn School of Medicine at Mount Sinai. Stop reason: OTHER/UNKNOWN.

No significant improvement in disease as graded by our assessments.

NCT06532136: Deucravacitinib Rosacea

Phase II Papulopustular Rosacea trial by Icahn School of Medicine at Mount Sinai. Stop reason: OPERATIONAL.

This study is being closed due to sponsor withdrawal of funding and support.

NCT04371393: MSCs in COVID-19 ARDS

Phase III Mesenchymal Stromal Cells trial by Icahn School of Medicine at Mount Sinai. Stop reason: EFFICACY/FUTILITY.

At 3d interim analysis, randomization, but not follow-up, was halted by the DSMB due to low predictive probability of achieving postulated mortality benefit (pre-specified 42.5% relative mortality reduction) were the trial to complete randomization.

NCT04388709: Interferon Lambda Therapy for COVID-19

Phase II SARS-CoV-2 trial by Icahn School of Medicine at Mount Sinai. Stop reason: OPERATIONAL.

Due to the number of competing trials at their site, the study team has closed enrollment and withdrawn this trial.